<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594188</url>
  </required_header>
  <id_info>
    <org_study_id>HEP201807</org_study_id>
    <nct_id>NCT03594188</nct_id>
  </id_info>
  <brief_title>Effects of Anesthetic Methods on Hepatic Cancer Cell Malignancy</brief_title>
  <official_title>Effects of Serum From Hepatocellular Carcinoma Surgery Patients Under Different Anesthetic Methods on Hepatic Cancer Cell Malignancy in Vitro</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Numerous studies found that anesthetic methods can influence the recurrence of tumor and the
      overall survival of patients after primary cancer surgery. Radiofrequency (RF) ablation is
      now widely used in clinic for treatment of hepatocellular carcinoma (HCC). Currently, diverse
      anesthetic methods, including general anesthesia (GA), epidural anesthesia and local
      anesthesia (LA), are used for RF ablation surgery. Using serum from HCC surgery patients
      randomized to receive either GA or LA during surgery, we investigated the effects of
      anesthetic methods on proliferation, migration and metastasis in HepG2 hepatic cancer cells
      in vitro.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">July 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cell proliferation</measure>
    <time_frame>1 hour post-surgery</time_frame>
    <description>HepG2 cells will be cultured with serum from patients undergoing RF ablation under GA or LA for 24h and cell proliferation will be measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>cell migration</measure>
    <time_frame>1 hour post-surgery</time_frame>
    <description>HepG2 cells will be cultured with serum from patients undergoing RF ablation under GA or LA and cell migration will be measured</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cell metastasis</measure>
    <time_frame>1 hour post-surgery</time_frame>
    <description>HepG2 cells will be cultured with serum from patients undergoing RF ablation under GA or LA and cell metastasis will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>general anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will have RF ablation for treatment of HCC under general anesthesia.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>local anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will have RF ablation for treatment of HCC under local anesthesia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>anesthetic methods</intervention_name>
    <description>Patients will receive standard GA or LA for RF surgery.</description>
    <arm_group_label>general anesthesia</arm_group_label>
    <arm_group_label>local anesthesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with a single primary liver tumor of 3cm or smaller, who are scheduled for RF
             ablation surgery

        Exclusion Criteria:

          -  less than 18 or more than 65 years old;

          -  ASA Physical Status 4 or greater;

          -  previous surgery in liver (including radiofrequency ablation);

          -  severe systemic disease (heart, lung, kidney, or immune system);

          -  INR&gt;1.5 or platelet count &lt;45,000 cells/mm3;

          -  a history of addiction to opioids;

          -  with known extension beyond the liver;

          -  Child-Pugh Class C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Renji Hospital affliated to Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Jie Tian</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

